STOCK TITAN

NewAmsterdam Pharma Company N.V. Ordinary Shares - $NAMS STOCK NEWS

Welcome to our dedicated page for NewAmsterdam Pharma Company N.V. Ordinary Shares news (Ticker: $NAMS), a resource for investors and traders seeking the latest updates and insights on NewAmsterdam Pharma Company N.V. Ordinary Shares stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NewAmsterdam Pharma Company N.V. Ordinary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NewAmsterdam Pharma Company N.V. Ordinary Shares's position in the market.

Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announces a public offering of ordinary shares and pre-funded warrants. The underwritten public offering aims to raise capital for the late-stage clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
-
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announced that CEO Michael Davidson and CFO Ian Somaiya will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on February 7, 2024. The company is a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated LDL-C. The webcast will be available through the investor relations section of the NewAmsterdam Pharma website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.01%
Tags
conferences
-
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) announces the appointment of William H. Lewis, J.D., M.B.A., as Chair of its Board of Directors. Mr. Lewis brings over 30 years of executive experience in the pharmaceutical and finance industries, and is known for his commitment to advancing new therapies for serious and rare diseases. NewAmsterdam is looking forward to his contributions as they advance their CETP inhibitor toward market and work to deliver a simple, oral, once-daily option to millions of people living with dyslipidemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.92%
Tags
management
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) provided an update on its clinical development programs, with three Phase 3 trial readouts expected over the next 18 months. The company is well-capitalized with cash to support operations through anticipated milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
none
-
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (NAMS) Completes Phase 3 Trial Enrollment, Reports Positive Alzheimer's Disease Biomarker Data, and Expands Leadership Team
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.91%
Tags
-
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. appoints Ian Somaiya as Chief Financial Officer. Somaiya brings extensive financial and operational expertise to the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.07%
Tags
management
Rhea-AI Summary
NewAmsterdam Pharma announces initial data from Phase 2a clinical trial for obicetrapib in early Alzheimer's disease patients with ApoE4 mutation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.71%
Tags
-
Rhea-AI Summary
NewAmsterdam Pharma CEO to participate in fireside chat at Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
conferences
-
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) appoints William "BJ" Jones as Chief Commercial Officer, signaling the company's strategic move to build a powerful commercial organization and prepare for the potential launch of obicetrapib, a promising oral therapy for patients at high risk of cardiovascular disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
management
Rhea-AI Summary
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS) announced positive clinical trial results for obicetrapib and ezetimibe, met primary endpoints with significant LDL-C reductions, and completed a secondary offering. The company's focus on pivotal Phase 3 trials and upcoming milestones indicates strong growth potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
NewAmsterdam Pharma Company N.V. Ordinary Shares

Nasdaq:NAMS

NAMS Rankings

NAMS Stock Data

1.95B
29.58M
5.77%
75.86%
0.38%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
NARRDEN